Rusyns

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Retrieved on: 
Saturday, August 6, 2022 - 1:50am

MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Key Points: 
  • MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.
  • MYFEMBREE is available immediately to patients with moderate to severe pain associated with endometriosis with a prescription from their healthcare provider.
  • Myovant and Pfizer also are committed to supporting women in the U.S. who are prescribed MYFEMBREE throughout their treatment journeys.
  • Food and Drug Administration for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Retrieved on: 
Thursday, May 26, 2022 - 11:45am

Receiving Fast Track designation from the FDA reinforces Pfizers belief in ervogastat/clesacostat as a potential treatment for NASH, a serious, progressive liver disease with no currently approved therapies, said James Rusnak, M.D., Ph.D., Senior Vice President and Chief Development Officer, Internal Medicine and Hospital, Pfizer.

Key Points: 
  • Receiving Fast Track designation from the FDA reinforces Pfizers belief in ervogastat/clesacostat as a potential treatment for NASH, a serious, progressive liver disease with no currently approved therapies, said James Rusnak, M.D., Ph.D., Senior Vice President and Chief Development Officer, Internal Medicine and Hospital, Pfizer.
  • The results of this study, which also includes arms investigating ervogastat as monotherapy, will inform a potential Phase 3 development program.
  • Diacylglycerol O-acyltransferase 2 (DGAT2) and acetyl-CoA carboxylase (ACC) are two key enzymes that regulate lipid metabolism.
  • At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

1847 Goedeker Inc. Appoints Jody Rusnak as Chief Merchandising and Brand Innovation Officer

Retrieved on: 
Monday, November 29, 2021 - 1:00pm

1847 Goedeker Inc. (NYSE American: GOED) ("Goedeker" or the "Company"), one of the largest specialty ecommerce players in the U.S. household appliances market, today announced that it has appointed Jody Rusnak as Chief Merchandising and Brand Innovation Officer.

Key Points: 
  • 1847 Goedeker Inc. (NYSE American: GOED) ("Goedeker" or the "Company"), one of the largest specialty ecommerce players in the U.S. household appliances market, today announced that it has appointed Jody Rusnak as Chief Merchandising and Brand Innovation Officer.
  • Mr. Rusnak will oversee the Companys efforts related to customer acquisition, marketing, merchandising strategy and related areas.
  • Albert Fouerti, Chief Executive Officer and Director, commented:
    As we continue implementing our ecommerce-focused strategy, establishing precise marketing and merchandising strategies will be critical.
  • Fortunately, Jody has the deep product expertise and merchandising background we need to take our customer acquisition and marketing efforts to the next level.

Neighborly Software Leads the Way in Distributing (Treasury) Rent, Mortgage and Utility Assistance

Retrieved on: 
Friday, August 27, 2021 - 6:00pm

Neighborly Software currently has 81 "Neighbors" (clients) utilizing our software for the first round of ERA funding, including the two largest State programs.

Key Points: 
  • Neighborly Software currently has 81 "Neighbors" (clients) utilizing our software for the first round of ERA funding, including the two largest State programs.
  • "Neighborly Software is doing amazing things with their ERA Program software.
  • "The New Mexico Mortgage Finance Authority has had a wonderful experience utilizing Neighborly Software for our rental and homeownership assistance programs.
  • Further, the Neighborly Software staff is helpful, responsive and extremely knowledgeable on programmatic requirements and how these requirements translate into software solutions.